What is Proov?
Proov operates at the intersection of biotechnology and consumer health, providing accessible, at-home diagnostic tools designed to empower women through every stage of their reproductive journey. Founded by Dr. Amy Beckley, the company addresses critical gaps in fertility tracking, specifically targeting luteal phase defects and ovulation quality. By translating complex clinical science into user-friendly, actionable data, Proov has established itself as a leader in the burgeoning FemTech industry. The company's market position is defined by its commitment to clinical rigor, enabling users to gain deeper insights into their hormonal health without the immediate necessity of invasive clinical interventions. This approach not only democratizes access to reproductive health information but also fosters a more proactive, data-driven model for personal wellness management.
How much funding has Proov raised?
Proov has raised a total of $9.7M across 1 funding round:
Series A
$9.7M
Series A (2021): $9.7M with participation from Portfolia FemTech II Fund, SteelSky Ventures, WCC Partners, Hambrecht Ducera Growth Ventures, Lightship Capital, and Gingerbread Capital
Key Investors in Proov
SteelSky Ventures
SteelSky Ventures is a visionary venture fund focused on investing in companies that enhance access, care, and outcomes in women's health, supporting innovations across consumer and digital health.
Lightship Capital
Lightship Capital invests in remarkable founders and entrepreneurs who innovate in U.S. regions, focusing on developing talent and catalyzing emerging ecosystems while believing that impact and profit can coexist.
Gingerbread Capital
Gingerbread Capital is dedicated to closing the funding gap for women-led ventures at early and growth stages, investing in exceptional founders across healthcare, consumer products, and education.
What's next for Proov?
Following this major enterprise-level funding, Proov is poised to scale its operational infrastructure and expand its product ecosystem. The strategic allocation of capital will likely focus on enhancing the company's digital health platform, integrating advanced analytics to provide more personalized health recommendations, and broadening its reach into underserved demographics. As the FemTech sector continues to mature, Proov's focus on evidence-based diagnostics provides a robust foundation for long-term growth. The company is expected to leverage these resources to strengthen its supply chain, invest in further clinical validation studies, and solidify its brand presence as a primary resource for women seeking to navigate their reproductive health with precision and autonomy. By maintaining its focus on high-impact, consumer-centric innovation, Proov is well-equipped to navigate the complexities of the healthcare market while delivering sustained value to its stakeholders.
See full Proov company page
